The FiberTAG project: Tagging dietary fibre intake by measuring biomarkers related to the gut microbiota and their interest for health

A. M. Neyrinck*, J. Rodriguez*, S. Vinoy†, V. Maquet‡, J. Walter§, S. C. Bischoff–, M. Laville** and N. M. Delzenne*

*Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université Catholique de Louvain, Brussels, Belgium; †Mondelez Int. R&D, Saclay, France; ‡KitoZyme S.A, Herstal, Belgium; §Department of Agricultural, Food & Nutritional Science and Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada; –Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany; **Centre de Recherche en Nutrition Humaine Rhône-Alpes, Univ-Lyon, Université Claude Bernard Lyon, Hospices Civils de Lyon, CENS, FCRIN/FORCE Network, CarMeN Laboratory, Lyon, France

Abstract

The scientific rationale for dietary fibre intake recommendations comes from the recognition of their benefits for health based on studies first published many years ago. It remains unclear which are the key physiological effects generated by dietary fibre in view of the diversity of the food components considered as dietary fibre, of the relevance of their classification (soluble and insoluble) and from the recent discoveries putting forward their interactions with the gut microbiota. The project FiberTAG (Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ 2017–2020 www.fibertag.eu) aims to establish a set of biomarkers (markers of gut barrier function and bacterial co-metabolites including volatile compounds and lipid derivatives), measured in different biological compartments (faeces, blood or breath) linking dietary fibre intake and gut microbiota-related health effects. The FiberTAG consortium brings together academic and industrial partners from Belgium, France, Germany and Canada to share data and samples obtained from existing as well as new intervention studies in order to evaluate the relevance of such biomarkers. The FiberTAG consortium is currently working on five existing cohorts (prospective observational or nutritional interventions in healthy or obese patients), and a number of new intervention studies to analyse the effect of insoluble dietary fibre (wheat bran and chitin-glucan, provided by the industrial partners) in healthy individuals or in obese patients at high cardiometabolic risk.

Keywords: biomarkers, chitin-glucan, dietary fibre, exhaled volatile organic compounds, microbiota, wheat bran

Introduction

Dietary fibre intake recommendations for adults range from 18 to 38 g per day; the World Health Organization/Food and Agriculture Organization (WHO/FAO)
and European Food Safety Authority (EFSA) recommend 25 g/day based on the amount needed for healthy laxation (EFSA 2010a; Jones 2014). The scientific rationale for dietary fibre recommendations derives from the recognition of their benefits for health based on studies first published many years ago. Dietary fibre is a broad category of non-digestible food ingredients that includes resistant starches, non-starch polysaccharides, oligosaccharides, lignin and analogous polysaccharides with associated health benefits (Stephen et al. 2017). Generally, dietary fibre is classified based on its solubility in water, microbial fermentation in the colon and viscosity (Stephen et al. 2017; Delzenne et al. 2019). The terms ‘soluble’ and ‘insoluble’ have been used in the literature to classify dietary fibres as viscous soluble in water (e.g. pectins), non-viscous soluble in water (e.g. inulin) or as water insoluble (e.g. cellulose) in an attempt to link different physical-chemical properties of fibre components to different physiological effects. However, the above classification is method-dependent, and water solubility does not always predict the physiological effects of dietary fibre (EFSA 2010b; Stephen et al. 2017). It remains unclear which are the key health physiological effects generated by insoluble dietary fibre, and whether they rely on the gut microbiota. The concept of prebiotics, initially elaborated with non-digestible oligosaccharides specifically fermented by gut bacteria (Gibson & Roberfroid 1995), was recently revisited by several partners of this project (Bindels et al. 2015a; Gibson et al. 2017). Prebiotics include fermentable dietary fibre which, through its interaction with the gut microbiota, modulates its composition and functions with beneficial effect for the host (Bindels et al. 2015a). On the basis of studies in animals and humans, it has been proposed that highly fermentable prebiotic dietary fibre might increase satiety, improve glucose tolerance and lipid metabolism and even control hypertension (EFSA 2010b; Delzenne et al. 2019). The mechanisms proposed to explain such effects often involve the bacterial metabolites or components capable of modification by prebiotic fibres. The identification of relevant biomarkers to assess these effects is thus a major objective.

Selection of relevant biomarkers of gut microbiota involved in metabolic disorders

The beneficial effect of the interactions between dietary fibre and the microbiota can result from the modulation of the production of bioactive metabolites, and/or from changes in the composition and functions of the gut microbiota that are supposed to mediate the fibre-derived health benefits. Several key intestinal functions can be influenced by gut microbiota and related metabolites, and therefore potentially influenced by dietary fibre, including gut barrier function, the gut endocrine function (production of incretins and gut hormones controlling appetite or energy metabolism), the gut immune system or even the digestive processes.

Gut barrier function has been identified as central in the control of host energy metabolism and the low- tone, metabolic inflammation (endotoxemia) that characterises a wide range of nutritional disorders (Delzenne et al. 2011a; Delzenne et al. 2011b; Geurts et al. 2013; Bischoff et al. 2014; Leclercq et al. 2014). Gut permeability can be assessed in vivo by the ingestion of inert marker molecules ($^{53}$Cr-EDTA, different sugars) (Bischoff et al. 2014; Wang et al. 2015). However, these tests are relatively complex and not always well accepted by patients. Moreover, they can be performed only in prospective trials. Therefore, other markers which can be measured in blood, urine or faeces are being tested in the FiberTAG project and are listed below:

- Lipopolysaccharide-binding protein (LBP) is a soluble acute-phase protein reflecting bacterial translocation (Bischoff et al. 2014; Wang et al. 2015).
- Albumin is the most abundant protein in blood and an increase of this protein in stool indicates a disturbed gut barrier (Bischoff et al. 2014; Wang et al. 2015). As albumin is sensitive to proteases, it is particularly adapted to assess the colon barrier function, where the gut microbiota is most abundant.
- Enteroocytes of the intestinal mucosal layer, involved in the uptake of fatty acids, produce the intestinal fatty acid binding protein (I-FABP) (Bischoff et al. 2014; Wang et al. 2015). This protein is specific for intestinal cells, and its measurement in the blood has been shown to be a marker of intestinal tissue injury.
- Calprotectin is a protein released by neutrophils and has been shown to be a marker of gut inflammation when measured in faeces (Bischoff et al. 2014; Wang et al. 2015).
- Zonulin is expressed in both liver and intestinal cells and has been shown to regulate the tight junctions. In the gut, it can be modulated by the microbiota (Bischoff et al. 2014; Wang et al. 2015). It can be measured in faeces, where a high concentration correlates with increased permeability.

These different markers are taken into consideration and analysed in existing cohorts, in order to (i) to test their relevance as gut barrier biomarkers versus gold-
standard (but more elaborate) methodologies and (ii) to evaluate their relationship with nutritional and biological outcomes of dietary fibre administration, including those linked directly to the gut microbiota.

We, and others, have evaluated the mechanisms of interactions between the gut microbiota and host gut physiology using animal pre-clinical models (Haub et al. 2010; Spruss et al. 2012; Ritze et al. 2014; Delzenne et al. 2015; Bindels et al. 2015b; Volynets et al. 2016). When fermented, dietary fibre can induce production of gases (e.g. CO₂, H₂, CH₄) and short-chain fatty acid (SCFA, e.g. acetate, propionate, butyrate) synthesis (Nakamura et al. 2010; Bischoff et al. 2014; Salazar Garzo et al. 2015; Heinritz et al. 2016). SCFAs can be absorbed and used as metabolic substrates or regulators in many organs through binding to specific G-coupled receptors. SCFA profile appears as an important signature of fibre fermentation, and the use of ¹³C-labelled substrates is needed to evaluate the relative contribution of specific fibre fermentation to SCFA production. Recent data suggest that other bioactive molecules, such as bile acids, conjugated polyunsaturated fatty acids (cPUFA) and volatile organic compounds (VOC) including indoles, phenols, nitrogen and sulphur metabolites, are involved in intestinal and metabolic integrity (Bischoff et al. 2014; Druart et al. 2014; Leclercq et al. 2014; Druart et al. 2015; Del et al. 2016; Wahlstrom et al. 2016).

Among the health effects attributed to dietary fibre, the interaction with dietary lipid compounds (steroids and fatty acids) is considered to be part of their physiological effects related to the control of blood lipids and energy metabolism. We showed that the profile of conjugated and trans fatty acid metabolites that result from the bacterial transformation of unsaturated fatty acids relates to the gut microbiota composition, since only specific bacteria (Roseburia spp. and lactobacilli), which can be increased by several dietary fibres, possess the enzymes needed to metabolise unsaturated fatty acids (Druart et al. 2014). In addition, bile acids participate in the metabolic relationship between the gut microbiota and host tissues (Kuipers et al. 2014). The gut microbiota is involved in bile acid profiling, namely through its reductase and hydrolase activity bile acids (Wahlstrom et al. 2016; Chavez-Talavera et al. 2017). Faecal bile acids are mainly non-conjugated due to their active deconjugation by the bacteria within the intestinal lumen. Bile acids are signalling molecules that regulate host metabolism and inflammation via the nuclear farnesoid X receptor (FXR) and the Takeda G protein-coupled receptor 5 (TGR5). These receptors activate transcriptional networks and signalling cascades controlling the expression and activity of genes involved in bile acid, lipid and carbohydrate metabolism, energy expenditure, and inflammation by acting predominantly in enterohepatic tissues, but also in peripheral organs (Chavez-Talavera et al. 2017).

A large panel of volatile compounds released in the breath is co-metabolites issued from gut microbiota and are therefore interesting biomarkers, potentially linking health to microbial breakdown of nutrients or endogenous substrates (Ajibola et al. 2013; Raninen et al. 2016). Selected ion flow tube-mass spectrometry (SIFT-MS) has been developed by members of our team as a powerful and sensitive analytical technique to rapidly quantify low levels of volatile metabolites, including SCFAs, which could explain the biological effect of fermentable dietary fibre.

Fermentable dietary fibre and prebiotics also induce specific compositional shifts to the gut microbiota (Deehan et al. 2017). According to the prebiotic concept, such specific stimulations are implicated in the health effects. However, strong associations between dietary fibre-induced microbiome shifts and relevant health markers or disease manifestations have not been established. FiberTAG will investigate links between dietary fibre-induced microbial signatures and relevant biomarkers to determine their potential value in predicting the physiological effects of dietary fibre. This will be performed using an ecological approach that considers the characteristics of gut microbiomes (high inter-individual variation, stability, resistance and resilience to perturbations) and the complex trophic interactions within the communities to evaluate how reliably the gut microbiota is associated with key gut biological functions (resulting in the development of appropriate bioinformatic tools).

Objectives of the FiberTAG Project

We are developing innovative approaches to reconsider the nutritional advice and concepts concerning the health effects of prebiotic dietary fibre, namely by examining whether insoluble dietary fibre also functions as a prebiotic dietary fibre. In the context of the FiberTAG project, we are finalising a dedicated database detailing the soluble and insoluble dietary fibre and prebiotic (oligo)saccharide (ITF, FOS and GOS) content of food products consumed in Europe. In addition, we are building a food frequency questionnaire which focuses on all types of dietary fibre intake for use in intervention, retrospective or prospective studies.

© 2020 The Authors. Nutrition Bulletin published by John Wiley & Sons Ltd on behalf of British Nutrition Foundation Nutrition Bulletin, 45, 59–65
Moreover, there is a crucial need to develop and validate new biomarkers associated with the various health effects of dietary fibre, which take into account their interaction with the gut microbiota. The *FiberTAG* project is developing experimental approaches in humans to cover those gaps using two approaches.

- First, the consortium is using existing cohorts to investigate the link between dietary fibre intake, gut microbial signature (the bacterial composition and the profile of key metabolites) and key gut biological functions such as gut barrier function.
- The second objective is to develop innovative approaches to evaluate in intervention studies the physiological effects of two different insoluble dietary fibres – one novel fibre specifically developed to interfere with gut microbiota (chitin-glucan) and one very frequently consumed in human diets (wheat bran) and capable of interacting with the gut microbiota.

**Approach and tools to evaluate the link between dietary fibre intake and microbial and metabolic signatures**

The overall organisation of the project is based on seven work packages (WPs), taking place over a period of 3 years (Figure 1).

The first objective focuses on five existing cohorts (see Table 1 for details of cohorts), for which some data (dietary questionnaires, anthropometric data and clinical biology) were already available. These cohorts, well-characterised and representative of different populations/phenotypes are being characterised for soluble/insoluble dietary fibre and prebiotic intake and used for the measurement of specific metabolites selected as biomarkers of fermentation in available samples (stool, urine and serum) and gut-related function and for faecal microbiota composition (using next-generation sequencing). Correlation studies

![Figure 1](https://example.com/fiber-tag-work-packages.png)
between biomarkers, gut microbiota and health outcomes with a special emphasis on gut barrier function, inflammation and cardiometabolic risk factors will allow the identification of those biomarkers that are the most relevant for evaluating the health effects of dietary fibre.

Exploring the metabolic signature of two selected insoluble fibres – wheat bran fraction and chitin-glucan – related to gut fermentation in humans

The second objective of the project is to evaluate in new intervention studies the potential relevance of two selected insoluble fibres (provided by the industrial partners) as modulators of host physiology through their interaction with the gut microbiota.

Chitin-glucan fermentation and related effects

The first intervention study consists of the evaluation of the fermentability of chitin-glucan in 15 healthy volunteers. Chitin-glucan, developed by KitoZyme (EFSA 2010c), has beneficial effects on the development of obesity and associated diabetes and hepatic steatosis in mice, through a mechanism related to the restoration of the composition and/or the activity of gut bacteria (Neyrinck et al. 2012). It modulates the human gut microbiota in the in vitro SHIME microbiota simulator (Marzorati & Possemiers 2017). This fibre is being tested in human volunteers in order to develop a non-invasive procedure for the measurement of volatile metabolites and gases in breath, reflecting the fermentation pattern of the dietary fibre.

Table 1 Descriptive characteristics of the five cohorts examined in the FiberTAG project

| Cohort | Country | Size (for FiberTAG) | Target population | Intervention/groups |
|--------|---------|---------------------|-------------------|---------------------|
| ALCOHOL | Belgium | 60 (30) | Subjects with a diagnosis of alcohol dependence according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition | Observational prospective study; 2 groups: subjects clinically evaluated by a psychiatrist and admitted to the gastroenterology ward for a 3-week detoxification and rehabilitation program (control group: 15 subjects age-, sex- and BMI-matched controls who socially consumed less than 20 g of alcohol per day). Duration: 3 weeks |
| FOOD4GUT | Belgium | 150 (50) | Obese subjects BMI >30 kg/m²; aged 18–65 years; with at least one of the following criteria: hypertension, (pre-) diabetes, dyslipidemia, liver steatosis | Simple blind parallel randomised placebo-controlled trial; 2 groups: 16 g/day of inulin with dietary advice to promote the consumption of vegetables rich in ITF or 16 g/day maltodextrin (control) with dietary advice provided to promote the consumption of vegetables poor in ITF. Duration: 3 months |
| FYBER | Canada | 220 (31) | Overweight to moderately obese subjects | Simple blind parallel randomised placebo-controlled trial; 2 groups: either corn arabinoxylan or microcrystalline cellulose (control); 35 g/day for males and 25 g/day for females. Duration: 6 weeks |
| LIBRE | Germany | 600 (200) | Female BRCA 1/2 mutation carriers, both with and without previous cancer diagnosis | Prospective, open, controlled intervention study; 2 groups: either intensive nutrition education with focus on Mediterranean diet, regular physical activity training or single nutrition information on healthy diet and physical activity (control). Duration: intervention: 3 months intensive (weekly intervention meetings), 9 months less intensive (monthly intervention meetings); follow-up: month 24 + 36, afterwards open-end follow-up |
| ObC | Germany | 100 (60) | Adults aged 18-65 years, BMI >30 kg/m², (Optifast52 programme) | Prospective observational uncontrolled study. All participants: Multidisciplinary weight loss programme comprising initial VLCD, nutrition education, behavioural modification and physical exercise. Duration: 1-year intervention, 2-year follow-up |

BMI, body mass index; BRCA 1/2, breast cancer 1/2; ITF, inulin-type fructan; VLCD, very-low calorie diet.
We are evaluating the gastrointestinal tolerance (by visual analogue scale) and the kinetics of exhaled gases and VOC (through SIFT-MS technology) over 12 hours as markers of fermentation following the ingestion of 4.5 g chitin-glucan compared with the ingestion of 4.5 g of maltodextrin (placebo). In a second intervention study, the effect of the chronic intake of chitin-glucan on gut microbiota composition and function is being assessed in the same healthy volunteers over 3 weeks. Daily chitin-glucan supplementation (4.5 g per day) versus maltodextrin will be given for 21 days with assessment of food intake and gastrointestinal tolerance, as well as faecal sampling for gut microbiota analysis. At day 0 (before intervention) and day 21 (after the intervention), the metabolites related to gut fermentation (exhaled gases and VOC after a test meal, bile acids, cPUFA, SCFAs in faeces) will be measured. This protocol evaluates the tolerance towards chitin-glucan in humans, its fermentability and its potential interaction with the gut microbiota composition and function. This study is a prerequisite to the third intervention, a randomised, controlled cross-over trial which aims to test the efficacy of the chitin-glucan intervention in the control of metabolism in metabolic risk individuals. For that purpose, 15 subjects (aged 30–65 years) male and female at cardiometabolic risk (abdominally obese, waist circumference >102 cm for men and >88 cm for women) will be selected.

Wheat bran fermentation

A wheat bran fraction has been provided and characterised by the industrial partner Mondelez, as an interesting source of fermentable insoluble dietary fibre (arabinoxylans). Indeed, wheat is one of the major cereal-based foods in occidental countries and increased knowledge about wheat bran fermentability will provide valuable information to promote its consumption in the general population. An enriched $^{13}$C-wheat bran has been produced to enable the fate of the $^{13}$C-labelled gut-derived metabolites in biological samples to be followed in a pilot study in healthy volunteers (Nazare et al. 2010; Vinoy et al. 2013). An in vivo pilot study is evaluating the extent and metabolic signature of the insoluble dietary fibre bran fermentation in six human healthy volunteers using $^{13}$C-wheat bran (biscuit prototype). For that purpose, we are analysing the kinetics of key exhaled gases in breath ($H_2$, $CO_2$, $CH_4$) and of $^{13}$C-metabolites and $^{13}$C-SCFAs released in the blood and faecal material after $^{13}$C-wheat bran ingestion. This innovative process will provide evidence on the relevance of fibre fermentation by observing the profile of $^{13}$C-metabolite production in blood and exhaled gases.

**Conclusions**

The FiberTAG project is in the last phase of development and will end in 2021. Some preliminary data have recently been communicated in several key meetings. We hope, as a consortium, that the huge amount of data obtained from existing and new cohorts will bring new insights in the way we envisage the contribution of insoluble fibre to the modulation of the gut microbiota, and in the identification of adequate biomarkers linking dietary fibre intake, gut microbiota modulation (including co-metabolite production) and health outcomes.

**Acknowledgement**

The FiberTAG project consortium also includes Julie-Anne Nazare, Maud Alligier and Anne-Ester Breyton from the Centre de Recherche en Nutrition Humaine Rhône-Alpes (Univ-Lyon, France), Zhengxiao Zhang from the Department of Medecine (University of Alberta, Canada), Benjamin Seethaler from Institute of Nutritional Medicine (University of Hohenheim, Germany), Alexandra Meynier from Mondelez Int. R&D (France).

**Conflict of interest**

The authors declare that they have no competing interests.

**Funding**

FiberTAG project was initiated from a European Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ (JPI HDHL). Funding for this article is provided by the Service Public de Wallonie (SPW-DGO6, convention 1610365, Belgium), the Agence Nationale de la Recherche (ANR, France), the Canadian Institutes of Health Research (CIHR, Canada) and German Federal Ministry for Education and Research (BMBF, Germany).

**References**

Ajobola OA, Smith D, Spanel P et al. (2013) Effects of dietary nutrients on volatile breath metabolites. *Journal of Nutritional Science* 2: e34.

Bindels LB, Delzenne NM, Cani PD et al. (2015a) Towards a more comprehensive concept for prebiotics. *Nature Reviews Gastroenterology & Hepatology* 12: 303–10.

Bindels LB, Walter J & Ramer-Tait AE (2015b) Resistant starches for the management of metabolic diseases. *Current Opinion in Clinical Nutrition & Metabolic Care* 18: 559–65.

Bischoff SC, Barbara G, Buurman W et al. (2014) Intestinal permeability—a new target for disease prevention and therapy. *BMC Gastroenterology* 14: 189.
Chavez-Talavera O, Tailleux A, Lefebvre P et al. (2017) Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152: e1673.

Deehan EC, Duar RM, Arnet AM et al. (2017) Modulation of the gastrointestinal microbe with nondigestible fermentable carbohydrates to improve human health. Microbiometry Spectrum 5. https://doi.org/10.1128/microbiolspec.BAD-0019-2017

Del CF, Nobili V, Vernocchi P et al. (2016) Gut microbiota profiling of pediatric NAFLD and obese patients unveiled by an integrated meta-omics based approach. Hepatology 64: 451–64.

Delzenne NM, Neyrinck AM, Backhed F et al. (2011a) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nature Reviews Endocrinology 7: 639–46.

Delzenne NM, Neyrinck AM & Cani PD (2011b) Modulation of gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microbial Cell Factories 10: S10.

Delzenne NM, Cani PD, Everard A et al. (2015) Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia 58: 2206–17.

Delzenne NM, Olives M, Neyrinck AM et al. (2019) Nutritional interest of dietary fiber and prebiotics in obesity: Lessons from the MyNewGut consortium. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2019.03.002

Druart C, Dewulf EM, Cani PD et al. (2014) Gut microbial metabolites of polyunsaturated fatty acids correlate with specific fecal bacteria and serum markers of metabolic syndrome in obese women. Lipids 49: 397–402.

Druart C, Bindels LB, Schmalz R et al. (2015) Ability of the gut microbiota to produce PUFA-derived bacterial metabolites: Proof of concept in germ-free versus conventionalized mice. Molecular Nutrition & Food Research 59: 1603–13.

EFSA (European Food Safety Authority) (2010a) Scientific Opinion on Dietary Reference Values for carbohydrates and dietary fibre. EFSA Journal 8: 1462.

EFSA (European Food Safety Authority) (2010b)Scientific Opinion on the substantiation of health claims related to dietary fibre (ID 744, 745, 746, 748, 749, 753, 803, 810, 855, 1415, 1416, 4308, 4330) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 8: 1735.

EFSA (European Food Safety Authority) (2010c) Scientific Opinion on the safety of ‘Chitin-glucan’ as a Novel Food ingredient. EFSA Journal 8: 1687.

Geurts L, Neyrinck AM, Delzenne NM et al. (2013) Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics. Beneficial Microbes 5: 1–15.

Gibson GR & Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. Journal of Nutrition 125: 1401–12.

Gibson GR, Hutkins R, Sanders ME et al. (2017) Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology 14: 491–302.

Haub S, Kanuri G, Volynets V et al. (2010) Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. American Journal of Physiology - Gastrointestinal and Liver Physiology 298: G335–44.

Heinritz SN, Weiss E, Eklund M et al. (2016) Intestinal microbiota and microbial metabolites are changed in a pig model fed a high-fat/low-fiber or a low-fat/high-fiber diet. PLoS One 11: e0154329.

Jones JM (2014) CODEX-aligned dietary fiber definitions help to bridge the ‘fiber gap’. Nutrition Journal 13: 34.

Kuipers F, Bloks VW & Groen AK (2014) Beyond intestinal soap-bile acids in metabolic control. Nature Reviews Endocrinology 10: 488–98.

Leclercq S, Matamoros S, Cani PD et al. (2014) Intestinal permeability, gut dysbacteriosis, and behavioral markers of alcohol-dependence severity. Proceedings of the National Academy of Sciences of the United States of America 111: E4485–93.

Marzorati MMV & Possemiers S (2017) Fate of chitin-glucan in the human gastrointestinal tract as studied in a dynamic gut simulator (SHIME®). Journal of Functional Foods 30: 313–20.

Nakamura N, Lin HC, McSweeney CS et al. (2010) Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease. Annual Review of Food Science and Technology 1: 363–95.

Nazare JA, de RA, Normand S, et al. (2010) Effect of postprandial modulation of glucose availability: short- and long-term analysis. British Journal of Nutrition 103: 1461–70.

Neyrinck AM, Possemiers S, Verstraete W et al. (2012) Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. The Journal of Nutritional Biochemistry 23: 51–59.

Raninen KJ, Lappi JE, Mulkala ML et al. (2016) Fiber content of diet affects exhaled breath volatiles in fasting and postprandial state in a pilot crossover study. Nutrition Research 36: 612–19.

Rizke Y, Bardos G, Claus A et al. (2014) Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS ONE 9: e80169.

Salazar Garzo N, Dewulf EM, Neyrinck AM et al. (2015) Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women. Clinical Nutrition 34: 501–7.

Spruss A, Kanuri G, Stahl C et al. (2012) Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Laboratory Investigation 92: 1020–32.

Stephen AM, Champ MM, Cloran SJ et al. (2017) Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. Nutrition Research Reviews 30: 149–90.

Vinoy S, Normand S, Meynier A et al. (2013) Cereal processing influences postprandial glucose metabolism as well as the GI effect. Journal of the American College of Nutrition 32: 79–91.

Volynets V, Reichold A, Bardos G et al. (2016) Assessment of the intestinal barrier with five different permeability tests in healthy C57BL/6J and BALB/cJ Mice. Digestive Diseases and Sciences 61: 737–46.

Wahlstrom A, Sayin SI, Marschall HU et al. (2016) Intestinal Cross-talk between Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metabolism 24: 41–50.

Wang L, Llorente C, Hartmann P et al. (2015) Methods to determine intestinal permeability and bacterial translocation during liver disease. Journal of Immunological Methods 421: 44–53.